Imcyse, a clinical-stage biopharmaceutical company developing a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, has entered into a research collaboration and license agreement with Pfizer Inc. for Imcyse’s Rheumatoid Arthritis (RA) program based on the company’s Imotope technology.   Following the successful completion of a research collaboration initiated in 2017, the companies have entered into this license agreement to develop Im...